We present KnowEnG, a free-to-use computational system for analysis of genomics data sets, designed to accelerate biomedical discovery. It includes tools for popular bioinformatics tasks such as gene prioritization, sample clustering, gene set analysis and expression signature analysis. The system offers 'knowledge-guided' data-mining and machine learning algorithms, where user-provided data are analyzed in light of prior information about genes, aggregated from numerous knowledge-bases and encoded in a massive 'Knowledge Network'. KnowEnG adheres to 'FAIR' principles: its tools are easily portable to diverse computing environments, run on the cloud for scalable and cost-effective execution of compute-intensive and data-intensive algorithms, and are interoperable with other computing platforms. They are made available through multiple access modes including a web-portal, and include specialized visualization modules. We present use cases and re-analysis of published cancer data sets using KnowEnG tools and demonstrate its potential value in democratization of advanced tools for the modern genomics era.
Introduction
The rapid growth of genomics data sets 1 and efforts to consolidate diverse data sets into common portals 2 have created an urgent need today for software frameworks that can be easily applied to these genomic 'big data' to extract biological and medical insights from them 3 . Here, we present 'KnowEnG' (Knowledge Engine for Genomics, pronounced 'knowing'), a cloud-based engine that 2 provides a suite of powerful and easy-to-use machine-learning tools for analysis of genomics data sets. These tools, also referred to as 'pipelines', are geared towards data sets represented as spreadsheets or tables (genes x samples) that record typical genomic profiles such as gene expression, mutation counts, etc. for a collection of samples, at the resolution of individual genes.
The pipelines help identify biologically meaningful patterns in the provided spreadsheet data, through ab initio analysis as well as by contextualizing with prior knowledge. Here, we demonstrate the capabilities of KnowEnG by using it for common bioinformatics analyses such as patient stratification, gene prioritization, gene set characterization and signature analysis on two major data sets in cancer genomics 4, 5 , and reproducing key results of the original studies as well as gleaning new biological insights. In doing so, we hope to highlight both the sophisticated level of analysis possible and the ease-of-use with which multiple pipelines can be invoked, individually as well as in combination, to generate a multi-faceted narrative of the insights that the data have to offer.
Diverse computing environments for KnowEnG:
The genomics computing infrastructure of the future has to be adapted to the diverse ecosystem of data sets and tools that will continue to flourish in genomic research. In particular, tools must be 'findable, accessible, interoperable and reusable' 6 , i.e., comply with the 'FAIR' principles that guide the modern vision of biological data science. In recognition of these principles, software components of the KnowEnG system are packaged using state-of-the-art technology 7 that makes them highly portable and amenable to scalable execution in varying computing environments. A convenient way to access the system is through a web portal that links to a KnowEnG server (Supplementary Note SN1) running on Amazon Web Services (AWS). A user can upload their genomics data set as a spreadsheet and then execute available pipelines (Supplementary Note SN2 and Figure 1A , B). Often, the results of one KnowEnG pipeline can be further analyzed using another pipeline, and the system facilitates such 'handover' between pipelines ( Figure 1D ). For added security and control, users may also create a personal instance of the KnowEnG server and web portal using their AWS accounts (Supplementary Note SN3). This design feature can help meet challenges of heavy computing loads faced by a public analytics server. Computationally savvy users may invoke the pipelines and avail of additional functionalities through Jupyter notebooks 8 from a dedicated KnowEnG server. A third mode of access, created for cancer researchers, is via the NCI Cancer Genomics Cloud Resource built by Seven Bridges (SB-CGC) 9 , where users may directly access large cancer data sets, such as those generated by the NCI TCGA program 10 , and analyze them using KnowEnG pipelines without transferring the data from AWS. Through these varied access 4 of samples that represent distinct biological or pathological states 14 ; patient stratification in cancer, where subtypes are defined based on molecular markers 15 , is a prime example. The same clustering tools are often applied to different types of genomic profiles, including gene expression, mutation counts, copy number mutations, etc 4 . However, clustering of somatic mutation profiles of cancer patients presents a significant obstacle, since each profile is sparse (a minuscule fraction of genomic loci are mutated) and has little direct similarity to other profiles. As an example of a data set that presents this challenge, we worked with somatic mutation profiles of 3276 tumor , and even here the largest cluster had over 70% of the samples;
we will refer to this below as the standard clustering. This initial analysis illustrates the challenge in clustering somatic mutation profiles: due to their high dimensionality and sparsity, biologically related profiles often do not harbor shared mutations and are not grouped together 18 , ultimately leading to many small and one or few large clusters.
Knowledge-guided clustering of mutation profiles: Knowledge-guided clustering powered by the Knowledge Network offers a possible solution to the problem just noted. Here, prior knowledge of gene-gene relationships encoded in the network is used to recognize when somatic mutations in different genes may be functionally related, thus allowing more subtle forms of similarity between mutation profiles to be exploited in grouping patients. The knowledge-guided option of the Sample Clustering pipeline (Figure 2A ) implements the 'Network-based Stratification' (NBS) algorithm of Hofree et al.
18
, where a random walk method makes patient mutation profiles less sparse by borrowing information from the Knowledge Network before the actual clustering step. We used knowledge-guided clustering with the HumanNet Integrated network ('hnInt') 19 20 between the clusters and tumor types and repeated the process for other approaches to sample clustering, including the multi-omics ClusterOf-Cluster-Assignment (COCA) clustering reported in Hoadley et al. 4 ( Figure 2C ). Interestingly, while there is a high concordance between tumor type and the COCA cluster labels of Hoadley et al. 4 (ARI = 0.82), the same is not true for NBS-based clusters from the KnowEnG pipeline (ARI = 0.13) or for the pathway-based clustering of mutation profiles in the original study (ARI = 0.13).
In other words, knowledge-guided clustering finds groups of patient mutation profiles that have strong correspondence with survival characteristics yet do not simply track tumor types, suggesting alternative levels of molecular similarity. We explored this possibility in detail (Supplementary Note SN7), and found the clusters to be characterized by mutations in genes from specific and distinct pathways, even when they are mixed in terms of tumor type representation.
Clustering of multi-omics data:
The standard clustering pipeline in KnowEnG may be applied to any type of spreadsheet data to cluster a collection of samples, while the knowledge-guided clustering pipeline may be used on any gene-level spreadsheet, where rows represent genes.
We showcase this capability by performing 'multi-omics clustering' of the same cohort of patients 
Case study: Gene Prioritization for tumor types
A routinely conducted analysis of high-throughput omics profiles is in the determination of genes associated with particular phenotypic conditions or biological processes of interest. Discovery of differentially expressed genes 25 by contrasting transcriptomic profiles before and after treatment or in case versus control experiments, or of genes whose expression correlates with a numeric phenotype such as drug response 26 are prime examples. The Gene Prioritization pipeline in KnowEnG offers this functionality, given a spreadsheet of omics data (genes x samples) and a 'phenotype spreadsheet' (phenotypes x samples) that represents one or more phenotypic labels for each sample in the omics spreadsheet. As a simple demonstration of this pipeline, we analyzed expression data from tumor samples in the pancan12 data set introduced above, comparing each tumor type with all others using a t-test to identify significant differences in individual gene expression between the groups; this is the standard version of the pipeline ( Figure   3A , Supplementary Method SM7).
Knowledge-guided gene prioritization:
KnowEnG also offers a knowledge-guided mode of this pipeline, where the ProGENI algorithm of Emad et al. 27 is used to incorporate a network encoding prior knowledge into the identification of phenotype-related genes ( Figure 3A ), using random walk-based techniques similar to those used in the NBS clustering approach 18 . We had previously tested ProGENI on the task of prioritizing drug response-related genes. Through systematic benchmarking, experimental validations and literature surveys we showed that it identifies phenotype-related genes more accurately compared to simple statistical methods as well as 8 machine learning methods that do not utilize prior knowledge 28 . We now applied this algorithm, via the knowledge-guided gene prioritization pipeline, to identify top genes associated with each tumor type, based on expression data ( Figure 3B , Supplementary Method SM7). (KnowEnG allows this analysis to be performed for all tumor types through one simple operation, rather than repeat it for each tumor type separately.)
Gene prioritization finds driver genes: For an independent assessment of the above results, we compared the top 100 genes for each tumor type with drivers of that cancer as cataloged in the IntOGen database 29 based on mutation and gene fusion data ( Figure 3C ). We observed overlaps between the two lists; for example, in head and neck squamous cell carcinoma (HNSCC) six of the highly prioritized genes are known drivers (Fisher's exact test p-value 8.2E-4, Supplementary
Figure SM8.SF1).
A similar assessment of genes reported by the standard pipeline (without knowledge-guidance) revealed fewer overlaps with respective driver sets for all but two tumor types ( Figure 3C ). Often, common driver genes were identified by both versions of the pipeline, e.g., GATA3 for breast cancer (BRCA), but in many cases the knowledge-guided version reported known drivers that were missed by the standard pipeline, e.g., FOXA1 for BRCA, NRAS, and KRAS for acute myeloid leukemia (AML), and CDH1, CTNNB1 and EGFR for HNSCC. (ESR1, a well known marker of BRCA 30 , was ranked in the top 1.2% of all genes for BRCA, but ranked much worse for other tumor types.) Similar conclusions were reached when we repeated the assessment using a larger external set of tumor type drivers, based on both IntOGen and COSMIC databases 29, 31 (Supplementary Method SM7).
Functional enrichment of prioritized genes:
To gain further insights into the highly ranked genes reported for each tumor type in the above analysis, we subjected them to functional enrichment analysis through the Gene Set Characterization pipeline, whose standard version uses the Fisher's exact test to assess the enrichment of a gene set for pre-specified annotations. This revealed various interesting pathways and Gene Ontology terms as being significantly associated with each tumor type (Supplementary Method SM8). For instance, glioblastoma (GBM)-related genes found by ProGENI were significantly associated with receptor proteins in the presynaptic active zone and excitatory synapse, whose altered expression can enhance gliomas ability to grow and survive 32 (Bonferroni corrected p-value 6.0E-3). Similarly, Acute Myeloid Leukemia (AML)-related genes were enriched for platelet activation, shown to be related to blast proliferation 33 (Bonferroni corrected p-value 2.0E-6). The extent to which significant functional properties can be associated with a gene set extracted by genomics analyses is one measure of the utility of that gene set 34 . Thus, we summarized the results of gene set characterization by noting the most statistically significant functional enrichment (of genes prioritized) for each tumor type. We noted that when the same process was repeated using genes reported by the standard gene prioritization pipeline the functional enrichments tended to be less prominent ( Figure 3D with the data on the SB-CGC, we reran the analysis by simply substituting an alternate TCGA dataset of LUSC tumor samples, again finding the classical subtype (40%) to be the most prevalent ( Figure 4D ).
Pathway analysis of subtype-associated genes:
Having categorized ESCC patients into one of four subtypes using signature analysis, we next used the standard gene prioritization pipeline to identify genes associated with each subtype, and subjected the resulting subtype-associated gene lists (Supplementary Method SM11) to further analysis using the gene set characterization pipeline introduced above. We now used the knowledge-guided version of this pipeline, which instead of performing the traditional 'enrichment test' between sets 40 , uses a random-walk algorithm with the user-provided gene set as 'restart nodes', to find property nodes of the Knowledge Network that are most related to the given gene set ( Figure 5A ). This class of algorithms has been successfully used to quantify the relationship between network nodes in a variety of domains such as web mining 41 and social network analysis 42 . The KnowEnG pipeline uses an implementation called 'DRaWR' 43 , the main advantage of which compared to enrichment tests is that it examines not only properties with which the given genes are annotated, but also the properties with which genes related to the given genes are annotated (Supplementary
Method SM11).
We have previously used DRaWR to characterize gene sets in Drosophila development 43 and cancer 44 . Here, we used the DRaWR-based knowledge-guided gene set characterization pipeline with the HumanNet Integrated network 19 as the underlying network to identify, for ESCC subtype-related genes, the most related pathways in the Enrichr Pathways . Figure 5C tabulates 12 discovered pathway associations for ESCC subtypes that were reported by the DRaWR-based version of the pipeline, but not by the standard version. Even though these associations do not meet the traditional criterion of significant set overlap, there is support in the literature for seven of the 12 associations. Moreover, the top-ranked association was between basal subtype of ESCC and the gastric cancer network, which is credible given the close relationship between ESCC and gastric cancer (GCA), which are anatomically adjacent and share several risk factors 47 . Surprisingly, this association was not detected by the enrichment test performed in the standard pipeline. Another interesting example is the primitive subtype being linked to FOXM1 transcription factor network, but only by the DRaWR-based pipeline. FOXM1
has been found to be related to ESCC progression 48 and to be a potential drug target; our finding of a specific association with the primitive subtype of ESCC suggests that the tumor subtype may be an important factor to consider in its therapeutic significance. We also found several subtypepathway associations reported by both versions of the pipeline ( Figure 5B ). For instance, both the basal and classical subtypes were associated with NRF2 pathway 49 , the secretory subtype was linked to Syndecan-1 mediated signaling event 50 , and the primitive subtype to oxidation by Cytochromes P450 51 . Six of the 13 such associations found by enrichment-based as well as DRaWR-based gene set characterization had circumstantial evidence in the literature.
In summary, this case study illustrates how different KnowEnG pipelines, in this case, beginning with signature analysis and followed by gene prioritization and gene set characterization, can be used in a workflow to not only relate patient profiles to previously reported cancer subtypes but also to glean novel insights about genes and pathways differentiating patients matched to different subtypes. We performed these analyses on a system external to KnowEnG (i.e., Seven Bridges CGC), but the same workflow may be executed on the KnowEnG platform as well, and the interface facilitates easy 'stringing' of multiple pipelines to enable such workflows.
Discussion
KnowEnG is an analysis engine designed and implemented with the needs and trends of modern offer useful online analysis of spreadsheet data, but these are typically intended for data sets stored on those portals. In contrast, the main target data for KnowEnG tools are those provided by the researcher, either by direct upload or by selection from an external repository such as SB-CGC.
KnowEnG also offers a vision of genomic computing that is complementary to the dominant paradigm where software packages (e.g., in R or python) are installed on the user's computer and executed locally. The current paradigm is convenient as long as data sets predominantly reside locally, but with the on-going movement towards massive data sets in the public domain 59 and a clear need for moving tools to co-locate with these data, we expect the alternative paradigm embraced by KnowEnG to be increasingly relevant. Its main platform provides a convenient way to analyze the user's uploaded spreadsheets while exploiting massive knowledge-bases encoded in the Knowledge Network, while its interoperability with major cloud-based platforms such as Seven Bridges CGC showcases the advantages of tools moving to data sources while maintaining the convenient 'illusion' of local computation. Finally, we note that while the case studies presented above are focused on cancer informatics, the tools of KnowEnG are applicable to a broad array of genomics data sets from a number of different species.
Methods
The details of the datasets and KnowEnG analysis pipelines used in this article are fully described in the Supplementary Methods. The Supplementary Methods also includes additional interpretations for each analyses as well as all of the non-default run parameters needed to reproduce the results. Many subsections contain links to additional resources where the actual code, containers, or compute servers can be found. Additional information about the components of the KnowEnG platform and several related ad hoc analyses are also described in detail in the Supplementary Notes.
Data Availability
The datasets analyzed during this study are public Cancer Genome Atlas (TCGA) datasets available from the UCSC Cancer Genome Browser 58 or the Seven Bridges Cancer Genomics 
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